Nav: Home

Study shows universal vaccination has wiped out hepatitis B and associated liver cancer in Alaska's young people

August 09, 2017

Updated research presented at this year's World Indigenous Peoples' Conference on Viral Hepatitis in Anchorage, Alaska, USA (8-9 August) shows that the universal hepatitis B vaccination programme introduced for all newborn Alaskan children in the 1980s has wiped out hepatitis B infection and liver cancer cases associated with the infection. The study is by Dr Brian McMahon, Director of the Alaska Native Tribal Health Consortium (ANTHC) Hepatitis Program, Anchorage, AK, USA and colleagues at ANTHC including Dr Rosalyn Singleton.

Hepatitis B is a serious liver infection, which, if left untreated, becomes chronic, leading to extensive liver damage, liver cancer, and death. Since Hepatitis B is highly contagious, it spread rapidly in rural villages especially among young children.

In the 1970s and 1980s, Alaska Native (AN) people residing in Alaska experienced the highest rates of acute and chronic hepatitis B virus (HBV) infection and hepatocellular carcinoma (HCC - liver cancer) in the USA. In 1981-82, a HBV vaccine demonstration project providing HBV screening and vaccination was conducted in 2 highly endemic regions of Alaska. In 1984, the program was extended to AN people statewide, and AN infants in tribal health facilities were offered 3 doses of hepatitis B vaccine starting at birth. At the same time, a vaccine catch-up program was conducted in schools statewide and also included reminders for AN adults that had tested negative for the virus.

The authors of this updated research used data from the surveillance system set up in 1981 in tribal health facilities to detect acute HBV infections. Cases of HCC in young people aged 20 years and younger were identified using the US National Cancer Institute/CDC-funded cancer registry in place since 1969, combined with an active surveillance program screening those already known to be infected with HBV since 1982. Estimated vaccine coverage with 3 doses of hepatitis B vaccine among AN children living in Alaska was reported by the National Immunization Survey (NIS).

The data collected show that routine infant hepatitis B vaccination and mass screening have resulted in high levels of vaccine coverage in Alaskan AN children 19­35 months of age. The 1996 NIS estimated 3 dose hepatitis B vaccine coverage was higher among Alaskan AN children (94%) than the general U.S. population (82%), regardless of race. From 1996 to 2008, NIS­reported vaccine coverage among Alaska AN children has remained at a high level (87-99%).

The incidence of acute symptomatic HBV infection in AN persons aged 20 years and under decreased from 19 per 100,000 in 1981­1982 to no reported cases since 1992. The incidence of HCC in AN persons aged under 20 years decreased from 3 per 100,000 in 1984­1988 to no reported cases since 1998. The number of chronically infected HBV AN patients aged 20 years and under decreased from 657 in 1988 to just two cases in total since 1999, the last of those identified in 2010.

The authors say: "Universal newborn vaccination coupled with mass screening and immunisation of susceptible AN people has eliminated early­onset HCC and acute symptomatic HBV infection as a public health threat among AN children. This population­based approach can serve as a model for other populations."

They conclude: "The elements of this program that we introduced - which include screening and interventions to reduce perinatal transmission and universal vaccination- are recommended as the standard of care for all US populations, including Indigenous populations. Elimination in other populations, however, depends on the how effectively those interventions are applied, which might not be as comprehensive as took place in the AN tribal system."
-end-


World Hepatitis Alliance

Related Hepatitis Articles:

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.
Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.
Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
How to cure more hepatitis C patients
The cost of cures for hepatitis C have been prohibitive, but experts who served on an NAS panel have a solution that will save more patients and incentivize drug innovation.
Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic.
More Hepatitis News and Hepatitis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.